Nondopaminergic Neurotransmission in the Pathophysiology of Tourette Syndrome

Adamczyk, 2011, Genetic and functional studies of a missense variant in a glutamate transporter, SLC1A3, in Tourette syndrome, Psychiatric Genetics, 21, 90, 10.1097/YPG.0b013e328341a307 Alcantara, 2003, Localization of dopamine D2 receptors on cholinergic interneurons of the dorsal striatum and nucleus accumbens of the rat, Brain Research, 986, 22, 10.1016/S0006-8993(03)03165-2 Aliane, 2011, Key role of striatal cholinergic interneurons in processes leading to arrest of motor stereotypies, Brain: A Journal of Neurology, 134, 110, 10.1093/brain/awq285 Anderson, 1992, Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome, Advances in Neurology, 58, 123 Anderson, 1992, Brain monoamines and amino acids in Gilles de la Tourette’s syndrome: A preliminary study of subcortical regions, Archives of General Psychiatry, 49, 584, 10.1001/archpsyc.1992.01820070078016 Arnold, 2009, Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder, Psychiatry Research, 172, 136, 10.1016/j.pscychresns.2009.02.005 Arnold, 2004, Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: A preliminary study, Psychopharmacology, 174, 530, 10.1007/s00213-004-1847-1 Arnold, 2006, Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder, Archives of General Psychiatry, 63, 769, 10.1001/archpsyc.63.7.769 Barr, 1999, Genome scan for linkage to Gilles de la Tourette syndrome, American Journal of Medical Genetics, 88, 437, 10.1002/(SICI)1096-8628(19990820)88:4<437::AID-AJMG24>3.0.CO;2-E Behen, 2007, Abnormal brain tryptophan metabolism and clinical correlates in Tourette syndrome, Movement Disorders: Official Journal of the Movement Disorder Society, 22, 2256, 10.1002/mds.21712 Berding, 2004, [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients, Biological Psychiatry, 55, 904, 10.1016/j.biopsych.2004.01.005 Bredt, 2003, AMPA receptor trafficking at excitatory synapses, Neuron, 40, 361, 10.1016/S0896-6273(03)00640-8 Bruun, 1998, Paroxetine treatment of episodic rages associated with Tourette’s disorder, Journal of Clinical Psychiatry, 59, 581, 10.4088/JCP.v59n1104 Buse, 2013, Neuromodulation in Tourette syndrome: Dopamine and beyond, Neuroscience and Biobehavioral Reviews, 37, 1069, 10.1016/j.neubiorev.2012.10.004 Cath, 2013, Other psychiatric comorbidities in Tourette syndrome, 74 Cavallini, 2000, An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette’s syndrome, Psychiatry Research, 97, 93, 10.1016/S0165-1781(00)00220-1 Cavanna, 2012, Tolerability profile of clonidine in the treatment of adults with Tourette syndrome, Clinical Neuropharmacology, 35, 269, 10.1097/WNF.0b013e3182741c39 Cerqueira, 2007, The prefrontal cortex as a key target of the maladaptive response to stress, The Journal of Neuroscience, 27, 2781, 10.1523/JNEUROSCI.4372-06.2007 Chakrabarty, 2005, Glutamatergic dysfunction in OCD, Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 30, 1735, 10.1038/sj.npp.1300733 Chappell, 1996, Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette’s syndrome: Comparison to obsessive compulsive disorder and normal controls, Biological Psychiatry, 39, 776, 10.1016/0006-3223(95)00221-9 Chappell, 1994, Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture, Biological Psychiatry, 36, 35, 10.1016/0006-3223(94)90060-4 Chen, 1996, Excitatory actions of GABA in developing rat hypothalamic neurones, The Journal of Physiology, 494, 451, 10.1113/jphysiol.1996.sp021505 Connor, 1987, Depolarization- and transmitter-induced changes in intracellular Ca2+ of rat cerebellar granule cells in explant cultures, The Journal of neuroscience: The Official Journal of the Society for Neuroscience, 7, 1384, 10.1523/JNEUROSCI.07-05-01384.1987 Corbett, 2008, Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome, Psychoneuroendocrinology, 33, 810, 10.1016/j.psyneuen.2008.03.014 Coric, 2005, Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Biological Psychiatry, 58, 424, 10.1016/j.biopsych.2005.04.043 Craig, 2002, How do you feel? Interoception: The sense of the physiological condition of the body, Nature Reviews. Neuroscience, 3, 655, 10.1038/nrn894 Cubo, 2008, Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: An 18-week, single-center, dose-escalating, prospective, open-label study, Clinical Therapeutics, 30, 182, 10.1016/j.clinthera.2008.01.010 Cull-Candy, 2001, NMDA receptor subunits: Diversity, development and disease, Current Opinion in Neurobiology, 11, 327, 10.1016/S0959-4388(00)00215-4 Curtis, 2009, Cannabinoids for Tourette’s syndrome, The Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006565.pub2 Davies, 1979, Excitatory amino acid receptors and synaptic excitation in the mammalian central nervous system, Journal de physiologie, 75, 641 Dehning, 2010, A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome, Psychiatric Genetics, 20, 35, 10.1097/YPG.0b013e32833511ce Dickel, 2006, Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder, Archives of General Psychiatry, 63, 778, 10.1001/archpsyc.63.7.778 Dietl, 1998, Exacerbation of tics by prednisolone, Nervenarzt, 69, 1111, 10.1007/s001150050390 Ding, 2006, PET imaging of norepinephrine transporters, Current Pharmacological Design, 12, 3831, 10.2174/138161206778559687 Eapen, 1996, The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: Preliminary clinical experience, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 20, 737, 10.1016/0278-5846(96)00044-9 Ellender, 2011, Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine, The Journal of Neuroscience, 31, 15340, 10.1523/JNEUROSCI.3144-11.2011 Ercan-Sencicek, 2010, L-histidine decarboxylase and Tourette's syndrome, The New England Journal of Medicine, 362, 1901, 10.1056/NEJMoa0907006 Erickson, 2003, Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states, Neuroscience and Biobehavioral Reviews, 3, 233, 10.1016/S0149-7634(03)00033-2 Felling, 2011, Neurobiology of Tourette syndrome: Current status and need for further investigation, The Journal of Neuroscience, 31, 12387, 10.1523/JNEUROSCI.0150-11.2011 Fernandez, 2012, Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism, Biological Psychiatry, 71, 392, 10.1016/j.biopsych.2011.09.034 Ferreira, 2009, Differentiating attention-deficit/hyperactivity disorder inattentive and combined types: A (1)H-magnetic resonance spectroscopy study of fronto-striato-thalamic regions, Journal of neural transmission (Vienna, Austria: 1996), 116, 623, 10.1007/s00702-009-0191-3 Findley, 2003, Development of the Yale children’s global stress index (YCGSI) and its application in children and adolescents with Tourette syndrome and obsessive-compulsive disorder, Journal of American Academy of Child and, Adolescent Psychiatry, 42, 450, 10.1097/01.CHI.0000046816.95464.EF Freeman, 2000, An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries, Developmental Medicine & Child Neurology, 42, 436, 10.1017/S0012162200000839 Gadzicki, 2004, Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene, American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 127B, 97, 10.1002/ajmg.b.20159 Gilbert, 2006, Altered mesolimbocortical and thalamic dopamine in Tourette syndrome, Neurology, 67, 1695, 10.1212/01.wnl.0000242733.18534.2c Groeneweg, 2011, Rapid non-genomic effects of corticosteroids and their role in the central stress response, Journal of Endocrinology, 209, 153, 10.1530/JOE-10-0472 Haller, 2008, The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings, Frontiers in Neuroendocrinology, 29, 273, 10.1016/j.yfrne.2007.10.004 Handley, 1993, Serotonin and Tourette’s syndrome: Movements such as head-shakes and wet-dog shakes may model human tics, Advances in the Biosciences, 85, 235 Hardingham, 2002, Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways, Nature Neuroscience, 5, 405, 10.1038/nn835 Harris, 2006, Tic disorders: Neural circuits, neurochemistry, and neuroimmunology, Journal of Child Neurology, 21, 678, 10.1177/08830738060210080901 Hartmann, 2012, Increasing histamine neurotransmission in Gilles de la Tourette syndrome, Journal of Neurology, 259, 375, 10.1007/s00415-011-6171-1 Haugbøl, 2007, Cerebral 5-HT2A receptor binding is increased in patients with Tourette’s syndrome, The International Journal of Neuropsychopharmacology, 2, 245, 10.1017/S1461145706006559 Hauser, 1995, Sertraline-induced exacerbation of tics in Tourette’s syndrome, Movement Disorder, 10, 682, 10.1002/mds.870100529 Hayslett, 2003, Effects of donepezil on DOI-induced head twitch response in mice: Implications for Tourette syndrome, Pharmacology, Biochemistry, and Behavior, 76, 409, 10.1016/j.pbb.2003.08.015 Heinz, 1998, Tourette’s syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity, Neurology Journal, 51, 1069, 10.1212/WNL.51.4.1069 Hill, 2012, Endocannabinoid signaling, glucocorticoid-mediated negative feedback and regulation of the HPA axis, Neuroscience, 204, 5, 10.1016/j.neuroscience.2011.12.030 Hillmer, 2013, Measuring α4β2* nicotinic acetylcholine receptor density in vivo with [18F]nifene PET in the nonhuman primate, Journal of Cerebral Blood Flow Metabolism, 10.1038/jcbfm.2013.136 Hoekstra, 2013, Environmental factors in Tourette syndrome, Neuroscience and Biobehavioral Reviews, 37, 1040, 10.1016/j.neubiorev.2012.10.010 Joëls, 2009, The neuro-symphony of stress, Nature Reviews. Neuroscience, 10, 459, 10.1038/nrn2632 Jucaite, 2013, AZD5213: A novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects, The International Journal of Neuropsychopharmacology, 6, 1231, 10.1017/S1461145712001411 Kalanithi, 2005, Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome, Proceedings of the National Academy of Sciences of the United States of America, 102, 13307, 10.1073/pnas.0502624102 Kalisman, 2005, The neocortical microcircuit as a tabula rasa, Proceedings of the National Academy of Sciences of the United States of America, 102, 880, 10.1073/pnas.0407088102 Karagiannidis, 2013, Support of the histaminergic hypothesis in Tourette syndrome: Association of the histamine decarboxylase gene in a large sample of families, Journal of Medical Genetics, 10.1136/jmedgenet-2013-101637 Kataoka, 2010, Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome, The Journal of Comparative Neurology, 518, 277, 10.1002/cne.22206 Kim, 1996, Behavioral stress modifies hippocampal plasticity through N-methyl-d-aspartate receptor activation, Proceedings of the National Academy of Sciences of the United States of America, 93, 4750, 10.1073/pnas.93.10.4750 Kondo, 1978, Improvement in Gilles de la Tourette syndrome after corticosteroid therapy, Annals of Neurology, 4, 387, 10.1002/ana.410040423 Lau, 2007, NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders, Nature Reviews. Neuroscience, 8, 413, 10.1038/nrn2153 Leckman, 1986, Rebound phenomena in Tourette’s syndrome after abrupt withdrawal of clonidine. behavioral, cardiovascular, and neurochemical effects, Archives of General Psychiatry, 43, 1168, 10.1001/archpsyc.1986.01800120054011 Lerner, 2012, Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome, Brain: A Journal of Neurology, 135, 1926, 10.1093/brain/aws104 Liao, 2010, Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette syndrome, Pharmacogenomics, 12, 1733, 10.2217/pgs.10.160 Lin, 2007, Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/or obsessive-compulsive disorder, The Journal of Child Psychology and Psychiatry, 48, 157, 10.1111/j.1469-7610.2006.01687.x Lucas-Meunier, 2003, Cholinergic modulation of the cortical neuronal network, Pflügers Archiv / European Journal of Physiology, 446, 17, 10.1007/s00424-002-0999-2 Ludolph, 2008, Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: A 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study, NeuroImage, 41, 718, 10.1016/j.neuroimage.2008.02.025 Ludolph, 2012, Tourette syndrome and other tic disorders in childhood, adolescence and adulthood, Deutsches Ärzteblatt International, 109, 821 March, 2007, Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder, Biological Psychiatry, 61, 344, 10.1016/j.biopsych.2006.09.035 Monyer, 1994, Developmental and regional expression in the rat brain and functional properties of four NMDA receptors, Neuron, 12, 529, 10.1016/0896-6273(94)90210-0 Muller-Vahl, 1997, Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms, Der Nervenarzt, 68, 985 Muller-Vahl, 1998, Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome, Acta Psychiatrica Scandinavica, 98, 502, 10.1111/j.1600-0447.1998.tb10127.x Muller-Vahl, 2002, Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial, Pharmacopsychiatry, 35, 57, 10.1055/s-2002-25028 Muller-Vahl, 2005, Serotonin transporter binding in Tourette syndrome, Neuroscience Letters, 385, 120, 10.1016/j.neulet.2005.05.031 Muller-Vahl, 2003, Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial, The Journal of Clinical Psychiatry, 64, 459, 10.4088/JCP.v64n0417 Neuner, 2009, Tics and Tourette’s syndrome throughout the life span, Der Nervenarzt, 80, 1377, 10.1007/s00115-009-2807-0 Neuner, 2011, Neurobiology, clinical characteristics and therapy in Tourette’s syndrome, Fortschritte der Neurologie Psychiatrie, 79, 724 Niesler, 2005, Serotonin receptor genes HTR3A and HTR3B are not involved in gilles de la Tourette syndrome, Psychiatric Genetics, 15, 303, 10.1097/00041444-200512000-00015 Ogawa, 2009, Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT), Biological Pharmaceutical Bulletin, 32, 337, 10.1248/bpb.32.337 Oswald, 2005, Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine, Neuropsychopharmacology, 30, 821, 10.1038/sj.npp.1300667 Ozbay, 2006, Analysis of the dopamine beta hydroxylase gene in Gilles de la Tourette syndrome, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 141B, 673, 10.1002/ajmg.b.30393 Panula, 2013, The histaminergic network in the brain: Basic organization and role in disease, Nature Review Neuroscience, 14, 472, 10.1038/nrn3526 Paoletti, 2013, NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease, Nature Reviews. Neuroscience, 14, 383, 10.1038/nrn3504 Popielarska, 1972, On Gilles de la Tourette syndrome and therapeutic trials in the light of our observations, Pediatria Polska, 47, 1097 Popoli, 2011, The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission, Nature Review Neuroscience, 13, 22, 10.1038/nrn3138 Pringsheim, 2012, Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy, Canadian Journal of Psychiatry, 57, 133, 10.1177/070674371205700302 Rickards, 2009, Functional neuroimaging in Tourette syndrome, Journal of Psychosomatic Research, 67, 575, 10.1016/j.jpsychores.2009.07.024 Rickards, 1997, Seignot’s paper on the treatment of Tourette’s syndrome with haloperidol. Classic text no. 31, History of Psychiatry, 8, 433, 10.1177/0957154X9700803109 Roessner, 2011, ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment, European Child & Adolescent Psychiatry, 20, 173, 10.1007/s00787-011-0163-7 Sallee, 1996, Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette’s syndrome, Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1647, 10.1097/00004583-199612000-00017 Sandyk, 1995, Cholinergic mechanisms in gilles de la Tourette’s syndrome, The International Journal of Neuroscience, 81, 95, 10.3109/00207459509015301 Saporta, 2010, Multimodality neuroimaging in Tourette syndrome: Alpha-[11C] methyl-L-tryptophan positron emission tomography and diffusion tensor imaging studies, Journal of Child Neurology, 25, 336, 10.1177/0883073809339394 Scahill, 2009, Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness, CNS Drugs, 23, 43, 10.2165/00023210-200923000-00006 Scahill, 1997, Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: A double-blind placebo-controlled study, Journal of Child and Adolescent Psychopharmacology, 7, 75, 10.1089/cap.1997.7.75 Schmahmann, 2004, Disorders of the cerebellum: Ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome, The Journal of Neuropsychiatry and Clinical Neurosciences, 16, 367, 10.1176/appi.neuropsych.16.3.367 Shafii, 1986, The effects of sympathomimetic and antihistaminic agents on chronic motor tics and Tourette’s disorder, New England Journal of Medicine, 315, 1228, 10.1056/NEJM198611063151913 Shapiro, 1968, Treatment of Gilles de la Tourette’s syndrome with haloperidol, British Journal of Psychiatry, 114, 345, 10.1192/bjp.114.508.345 Silva, 1995, Environmental factors and realted fluctuation of symptoms in children and adolescents with Tourette’s disorder, The Journal of Child Psychology and Psychiatry, 36, 305, 10.1111/j.1469-7610.1995.tb01826.x Silvestri, 1994, Serotoninergic agents in the treatment of Gilles de la Tourette’s syndrome, Acta Neurologica (Napoli), 16, 58 Singer, 2010, Glutamatergic modulatory therapy for Tourette syndrome, Medical Hypotheses, 74, 862, 10.1016/j.mehy.2009.11.028 Singer, 2001, Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial, Neurology, 56, 599, 10.1212/WNL.56.5.599 Smith, 2006, The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress, Dialogues in Clinical Neuroscience, 8, 383, 10.31887/DCNS.2006.8.4/ssmith Sousa, 2008, Corticosteroid receptors and neuroplasticity, Brain Research Reviews, 57, 561, 10.1016/j.brainresrev.2007.06.007 Stahl, 2009 Swerdlow, 2005, Using animal models to develop therapeutics for Tourette syndrome, Pharmacology & Therapeutics, 108, 281, 10.1016/j.pharmthera.2005.05.003 Tashiro, 2008, Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin, British Journal of Clinical Pharmacology, 65, 811, 10.1111/j.1365-2125.2008.03143.x Threlfell, 2012, Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons, Neuron, 75, 58, 10.1016/j.neuron.2012.04.038 Tian, 2011, GABA- and acetylcholine-related gene expression in blood correlate with tic severity and microarray evidence for alternative splicing in Tourette syndrome: A pilot study, Brain Research, 1381, 228, 10.1016/j.brainres.2011.01.026 Tinaz, 2012, Reduced GABA in the sensorimotor cortex (SMC) of patients with Tourette syndrome (TS) as measured by H-magnetic resonance spectroscopy (MRS) [abstract], Movement Disorders, 27, 1341 Toren, 2005, Ondansetron treatment in Tourette’s disorder: A 3-week, randomized, double-blind, placebo-controlled study, The Journal of Clinical Psychiatry, 66, 499, 10.4088/JCP.v66n0413 TSAICG, 2007, Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families, American Journal of Human Genetics, 80, 265, 10.1086/511052 Tsigos, 2002, Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress, Journal of Psychosomatic Research, 53, 865, 10.1016/S0022-3999(02)00429-4 Tuomisto, 1991, Development of histaminergic neurons, 177 Van Ruitenbeek, 2013, Potential enhancing effects of histamine H1 agonism/H3 antagonism on working memory assessed by performance and bold response in healthy volunteers, British Journal of Pharmacology, 170, 144, 10.1111/bph.12184 Weeks, 1994, Tourette’s syndrome and the opioid system, The Lancet, 343, 1107, 10.1016/S0140-6736(94)90223-2 Wong, 2008, Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: Clues from an in vivo neurochemistry study with PET, Neuropsychopharmacology, 33, 1239, 10.1038/sj.npp.1301528 Ye, 2001, Ondansetron: A selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders, CNS Drug Reviews, 7, 199, 10.1111/j.1527-3458.2001.tb00195.x Yin, 2013, An experimental study on (131)I-CHIBA-1001: A radioligand for α7 nicotinic acetylcholine receptors, PLoS One, 8, e70188, 10.1371/journal.pone.0070188